Developer docs
API playgroundTry for free, no card

Search company profiles

virnext

Full company profile

uuid0099h22

Namestring
virnext
Legal namestring
Ezus Lyon 1
Websiteurl
virnext.fr
Company typeenum
Private
Founded yearint
2012
Descriptiontext

VirNext is a contract research organization (CRO) and technology research platform based in Lyon, France, operating as a spin-off of Ezus Lyon 1 (a subsidiary of Université Claude Bernard Lyon 1) within the VirPath academic laboratory. Founded around 2012, the company specializes in respiratory virology and provides a continuum of preclinical research services to pharmaceutical companies, biotechnology firms, and academic institutions. Its core operations include virus library curation, virus production across multiple cell-based and egg-based systems, virology services in BSL-2 and BSL-3 facilities, and preclinical evaluation using in vitro cell line models, 3D reconstituted human airway epithelium (MucilAir/Smallair via Epithelix), and in vivo animal models including NHPs (via partner Cynbiose). The platform has been validated by regulatory-level outcomes, notably contributing to EMA approval of HIPRA's BIMERVAX COVID-19 vaccine in April 2023.

VirNext generates revenue through two primary streams: fee-for-service contract research for vaccine and antiviral candidate evaluation, and technology licensing of its proprietary IP portfolio — most notably the METAVAC live-attenuated vaccine platform (licensed exclusively to spin-off Vaxxel) and diltiazem-based host-directed antiviral combinations (licensed to Signia Therapeutics). Pricing is project-based and quote-driven, with multi-year contracts typical. The customer base is horizontally segmented across pharmaceutical companies (primary), biotechnology firms (primary), and academic consortia (secondary), with the firm embedded in a network of collaborative research structures including RESPIVIR (France-Canada), ViroCrib, and the Cynbiome alliance.

The go-to-market model relies on scientific publications, conference participation (BioFIT, LIVE2024), and consortium-based partnership formation rather than traditional sales channels. The company operates with a 10-person multidisciplinary team led by Director Manuel Rosa-Calatrava (INSERM Director of Research) and has contributed to the creation of multiple spin-offs (Vaxxel, VirexpR, Signia Therapeutics, Nexomis, AIS Biotech), establishing an ecosystem-based commercialization model where new ventures are spun out independently rather than held as subsidiaries.

Short descriptiontext

VirNext is a Lyon-based B2B contract research organization and academic spin-off specializing in respiratory virology, providing virus production, preclinical evaluation models, and virology services in BSL-2/BSL-3 facilities to pharmaceutical companies, biotech firms, and academic institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLyon, France
HQ citystring
Lyon
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
respiratory virus research, preclinical evaluation services, antiviral testing services, vaccine development services, virus production services
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAJAIAI
Zoonotic & One Health Public Health Laboratory Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Testing Laboratories8734
Product category
Preclinical Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

VirNext provides fee-for-service research services including virus production, preclinical evaluation, and virology testing to pharmaceutical companies, biotech firms, and academic institutions. Revenue is generated through project-based contracts for evaluation of prophylactic and therapeutic candidates.

virnext.fr
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of proprietary technologies including METAVAC vaccine platform to spin-offs like Vaxxel. Revenue generated through exclusive worldwide licenses of patented technologies.

virnext.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom contract research services - pricing based on project scope
ModelOtherBilling cadenceMulti-year contract
Notes

No standard pricing tiers publicly available. Services are provided through direct B2B contracts with pharmaceutical companies, biotech firms, and academic institutions.

virnext.fr
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1SURVIR
Description

Automated platform for rapid characterization and quantification of emerging and re-emerging respiratory pathogens based on multiplex analysis.

virnext.fr
+1 more record
Core offering1 text field

VirNext is a technology research platform and contract research organization specializing in respiratory viruses. It provides fee-for-service virus production, virology testing, and preclinical evaluation of vaccine and antiviral candidates through in vitro cell line models, 3D reconstituted human airway epithelium (HAE) models, and in vivo animal models (mouse, ferret, hamster, non-human primate), all operated from integrated BSL-2 and BSL-3 facilities in Lyon, France.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Supported HIPRA BIMERVAX vaccine approval by EMA (April 2023) through preclinical studies demonstrating efficacy against SARS-CoV-2 variants
+2 more records
Product overview1 text field

VirNext is a technology research platform providing a comprehensive portfolio of virus-related research services and products for the pharmaceutical and biotechnology industries. The core offering consists of four interconnected service lines: (1) Virus Library – an extensive collection of respiratory virus strains; (2) Virus Production – manufacturing of high-quality viruses and vaccine antigens using cell-based and egg-based systems; (3) Virology Services – comprehensive testing services in BSL-2/BSL-3 facilities including viral detection, vaccine response assays, compound evaluation, and quality control; and (4) Preclinical Models – in vitro models (cell lines, human airway epithelium) and in vivo models (mouse, ferret, hamster, NHP) for evaluating prophylactic and therapeutic candidates. These products form an integrated continuum enabling customers to screen compounds, produce viruses, and evaluate candidates across predictive preclinical models from early discovery through preclinical development.

Product and service4 records
1Virus Library
CategoryContract Research Services
Description

An extensive respiratory virus collection including wild-type reference and recent clinical strains, recombinant reporter viruses, and strains covering influenza A/H1N1, A/H3N2, B/Yamagata, B/Victoria, SARS-CoV-2 variants, HMPV, RSV, coronavirus, parainfluenza, adenovirus, enterovirus, and rhinovirus, supplied to pharmaceutical and biotech research teams.

2Virus Production
CategoryContract Research Services
Description

Production of high-quality viruses and viral vaccine antigens using adherent cell cultures (A549, A549-ACE2, Hep-2, MDCK, Vero E6, LLC-MK2, HEK 293T, MRC-5), human airway epithelial cell cultures, and embryonated hen eggs at scales ranging from flasks to bioreactors (500 mL to 2 L), delivering viral supernatant, concentrated virus, purified virus, inactivated virus, split virus, and antigens.

3Virology Services
CategoryContract Research Services
Description

Comprehensive virology services performed in BSL-2 and BSL-3 facilities, including viral detection/quantification/characterization, vaccine response assays, infection and compound evaluation, quality control, epithelial fitness assessment, potency and antiviral testing, and drug combination studies, delivered to pharmaceutical and biotech clients.

4Preclinical Models
CategoryContract Research Services
Description

Integrated in vitro and in vivo preclinical models for evaluation of prophylactic and therapeutic candidates against respiratory viruses, combining cell line infection models, reconstituted human airway epithelium (HAE) models, and animal models (mouse, ferret, hamster, non-human primate) for translational research.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-10-11
Description

International Associated Laboratory between Université Claude Bernard Lyon 1 (France) and Université Laval/CHU de Québec (Canada). Formalized in October 2022 with INSERM joint lab label in 2024. Focuses on origin, treatment, and prevention of respiratory viral infections. Led by Manuel Rosa-Calatrava and Guy Boivin with 15+ years of collaboration history.

2ViroCrib Consortium
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

CNRS-initiated national screening infrastructure for antiviral molecules across complementary preclinical models. VirNext contributes viral library, combinatorial screening expertise, and continuum of predictive in vitro and in vivo infection models.

virnext.fr
3Cynbiose
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Public-private partnership since 2017 for evaluation of drugs, vaccines, and antibody candidates against respiratory viruses. Combines VirNext's in vitro/in vivo models with Cynbiose's NHP expertise for complete preclinical service packages.

virnext.fr
Strategic tierCoreTypeTechnology or Integration
Description

Partnership for in vitro SARS-CoV-2 and respiratory virus infection models based on reconstituted human respiratory tissues at air-liquid interface (MucilAir, Smallair). Epithelix provides 3D reconstituted human lung tissue; VirNext performs infections in BSL-3/BSL-2 facilities.

5Cynbiome Alliance
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Excellence preclinical research network dedicated to microbiome and infectious diseases. VirNext provides expertise in respiratory viruses and preclinical infection models. Led by Cynbiose with support from French government, BpiFrance, and Région Auvergne-Rhône-Alpes.

virnext.fr
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off from RESPIVIR and VirNext developing METAVAC live-attenuated intranasal vaccines against RSV and HMPV. Exclusive worldwide license for METAVAC platform. Founded 2019 in Lyon.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off licensing diltiazem-based antiviral compositions for treatment of influenza and SARS-CoV-2. Uses VirNext's SIGNATURA platform for drug identification and repurposing as broad-spectrum host-directed inhibitors.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off focused on indoor air quality and contamination management. Develops test benches for evaluating air treatment technologies against respiratory viruses. Founded from VirPath lab and VirNext platform expertise.

9Nexomis
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off launched 2024 providing bioinformatics and NGS data exploitation services. Technological support platform based on AI, mathematics, and system administration expertise.

virnext.fr
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off founded 2023 developing anti-infective therapeutics based on sugar-derived biopolymers. Lead candidate GlycoFlu for influenza. Leverages VirNext's virology expertise and preclinical capabilities.

11A*STAR Infectious Diseases Labs
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International partnership through IMMUNOVIR program structured around immune response studies, diagnostic technology development, and anti-infective immunotherapy strategies. Supported by PHCMERLION program between UCBL1 and A*STAR.

virnext.fr
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Spanish pharmaceutical company. VirNext performed preclinical evaluation of BIMERVAX COVID-19 vaccine candidate in NHP models, contributing to EMA approval in April 2023.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Research unit at Jean Monnet University (Saint-Étienne) focused on mucosal immunology, inflammation, and infection. Collaboration through RESPIVIR for mucosal vaccine and immunotherapy strategies.

14VirPath Laboratory
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Academic laboratory at CIRI (INSERM U1111 - CNRS UMR 5308) specializing in virology and human respiratory pathologies. Hosts National Reference Center for Respiratory Viruses. VirNext is spin-off (EZUS Lyon) of VirPath.

virnext.fr
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Deeptech company specialized in ultra-critical containment. Partner in SHIELD project for developing innovative controlled environment solutions for airborne infectious risk control in hospitals.

16CONIDIA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic and commercial partnership with VirexpR for assessing air treatment and respiratory protection technologies in atmospheres contaminated by infectious mixtures.

virnext.fr
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based CRO running human respiratory virus challenge trials and preclinical virology services for pharma and biotech. Comparable to VirNext on respiratory-virus specialization, BSL capability, and customer base of pharma/biotech developing antivirals and vaccines.

TypeBroad incumbent
Description

Global testing, inspection, and certification company with significant health and nutrition/pharmaceutical services including virology and BSL-2/BSL-3 testing. A broad incumbent whose scale and geographic reach compete with VirNext for outsourced virology services.

TypeDirect peer
Description

Dutch CRO specializing in respiratory virus and influenza preclinical/clinical services including BSL-3 capabilities and antiviral/vaccine evaluation. Closest functional peer to VirNext in Europe given overlapping respiratory-virus focus and similar contract-research service model.

TypeEmerging player
Description

US CRO focused on anti-infective and antiviral preclinical development, including respiratory virus evaluation and BSL-3 work. Comparable emerging specialized CRO with similar antiviral and vaccine candidate evaluation service lines.

5Cynbiose
TypeDirect peer
Description

French CRO specializing in non-human primate preclinical studies, VirNext's named NHP partner and member of the Cynbiome alliance. Directly comparable on BSL-3 in vivo respiratory virus evaluation and serves the same French/European biotech-pharma customer segment.

TypeBroad incumbent
Description

Global CRO offering end-to-end preclinical research including vaccine and antiviral safety/efficacy studies with BSL capabilities. A broad incumbent that competes with VirNext on bundled preclinical respiratory-virus programs from large pharma clients.

TypeDirect peer
Description

French preclinical CRO offering antiviral and virucidal testing services with BSL-2/BSL-3 capabilities, listed on VirNext's partner page. Directly comparable specialized respiratory/antiviral CRO competing for similar French and European biotech-pharma contracts.

TypeDirect peer
Description

Swiss provider of 3D reconstituted human airway epithelium models (MucilAir, Smallair) and respiratory toxicology/virology services. A named VirNext technology partner that competes and collaborates in HAE-based respiratory virus testing for pharma and cosmetics clients.

TypeEmerging player
Description

French biotech spin-off from RESPIVIR/VirNext developing METAVAC-based intranasal live-attenuated vaccines against RSV and HMPV. Comparable emerging vaccine developer leveraging VirNext's IP and platform; relevant peer as a downstream customer and proof point for VirNext's IP monetization model.

TypeEmerging player
Description

US-based infectious disease CRO offering in vivo and in vitro virology, immunology, and BSL-2/BSL-3 services for vaccines and antivirals. Comparable emerging specialized CRO with overlapping respiratory-virus and infectious-disease preclinical focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

virnext

Preclinical Research Servicesvirnext.fr

VirNext is a Lyon-based B2B contract research organization and academic spin-off specializing in respiratory virology, providing virus production, preclinical evaluation models, and virology services in BSL-2/BSL-3 facilities to pharmaceutical companies, biotech firms, and academic institutions.

What virnext does

VirNext is a contract research organization (CRO) and technology research platform based in Lyon, France, operating as a spin-off of Ezus Lyon 1 (a subsidiary of Université Claude Bernard Lyon 1) within the VirPath academic laboratory. Founded around 2012, the company specializes in respiratory virology and provides a continuum of preclinical research services to pharmaceutical companies, biotechnology firms, and academic institutions. Its core operations include virus library curation, virus production across multiple cell-based and egg-based systems, virology services in BSL-2 and BSL-3 facilities, and preclinical evaluation using in vitro cell line models, 3D reconstituted human airway epithelium (MucilAir/Smallair via Epithelix), and in vivo animal models including NHPs (via partner Cynbiose). The platform has been validated by regulatory-level outcomes, notably contributing to EMA approval of HIPRA's BIMERVAX COVID-19 vaccine in April 2023.

VirNext generates revenue through two primary streams: fee-for-service contract research for vaccine and antiviral candidate evaluation, and technology licensing of its proprietary IP portfolio — most notably the METAVAC live-attenuated vaccine platform (licensed exclusively to spin-off Vaxxel) and diltiazem-based host-directed antiviral combinations (licensed to Signia Therapeutics). Pricing is project-based and quote-driven, with multi-year contracts typical. The customer base is horizontally segmented across pharmaceutical companies (primary), biotechnology firms (primary), and academic consortia (secondary), with the firm embedded in a network of collaborative research structures including RESPIVIR (France-Canada), ViroCrib, and the Cynbiome alliance.

The go-to-market model relies on scientific publications, conference participation (BioFIT, LIVE2024), and consortium-based partnership formation rather than traditional sales channels. The company operates with a 10-person multidisciplinary team led by Director Manuel Rosa-Calatrava (INSERM Director of Research) and has contributed to the creation of multiple spin-offs (Vaxxel, VirexpR, Signia Therapeutics, Nexomis, AIS Biotech), establishing an ecosystem-based commercialization model where new ventures are spun out independently rather than held as subsidiaries.

virnext firmographics

Firmographics
Name
virnext
Legal name
Ezus Lyon 1
Website
https://virnext.fr
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
VirNext is a Lyon-based B2B contract research organization and academic spin-off specializing in respiratory virology, providing virus production, preclinical evaluation models, and virology services in BSL-2/BSL-3 facilities to pharmaceutical companies, biotech firms, and academic institutions.
Ownership category
akta.pro rank

virnext industry classification

Industry
Product category
Preclinical Research Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAJAIAI
Zoonotic & One Health Public Health Laboratory Networks
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Laboratories & Reference Testing Networks

Keywords

  • Respiratory virus research
  • Preclinical evaluation services
  • Antiviral testing services
  • Vaccine development services
  • Virus production services

Where virnext is headquartered

Location

Headquarters

HQ city
Lyon
HQ country
France
HQ region
Europe

Offices2 records

Markets served

virnext business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: VirNext provides fee-for-service research services including virus production, preclinical evaluation, and virology testing to pharmaceutical companies, biotech firms, and academic institutions. Revenue is generated through project-based contracts for evaluation of prophylactic and therapeutic candidates.
  2. Technology Licensing: Licensing of proprietary technologies including METAVAC vaccine platform to spin-offs like Vaxxel. Revenue generated through exclusive worldwide licenses of patented technologies.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom contract research services - pricing based on project scope

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

virnext product offering

Product offering

Core offering

VirNext is a technology research platform and contract research organization specializing in respiratory viruses. It provides fee-for-service virus production, virology testing, and preclinical evaluation of vaccine and antiviral candidates through in vitro cell line models, 3D reconstituted human airway epithelium (HAE) models, and in vivo animal models (mouse, ferret, hamster, non-human primate), all operated from integrated BSL-2 and BSL-3 facilities in Lyon, France.

Product overview

VirNext is a technology research platform providing a comprehensive portfolio of virus-related research services and products for the pharmaceutical and biotechnology industries. The core offering consists of four interconnected service lines: (1) Virus Library – an extensive collection of respiratory virus strains; (2) Virus Production – manufacturing of high-quality viruses and vaccine antigens using cell-based and egg-based systems; (3) Virology Services – comprehensive testing services in BSL-2/BSL-3 facilities including viral detection, vaccine response assays, compound evaluation, and quality control; and (4) Preclinical Models – in vitro models (cell lines, human airway epithelium) and in vivo models (mouse, ferret, hamster, NHP) for evaluating prophylactic and therapeutic candidates. These products form an integrated continuum enabling customers to screen compounds, produce viruses, and evaluate candidates across predictive preclinical models from early discovery through preclinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • SURVIR: Automated platform for rapid characterization and quantification of emerging and re-emerging respiratory pathogens based on multiplex analysis.
  • METAVAC

Products and services

  • Virus Library An extensive respiratory virus collection including wild-type reference and recent clinical strains, recombinant reporter viruses, and strains covering influenza A/H1N1, A/H3N2, B/Yamagata, B/Victoria, SARS-CoV-2 variants, HMPV, RSV, coronavirus, parainfluenza, adenovirus, enterovirus, and rhinovirus, supplied to pharmaceutical and biotech research teams.
  • Virus Production Production of high-quality viruses and viral vaccine antigens using adherent cell cultures (A549, A549-ACE2, Hep-2, MDCK, Vero E6, LLC-MK2, HEK 293T, MRC-5), human airway epithelial cell cultures, and embryonated hen eggs at scales ranging from flasks to bioreactors (500 mL to 2 L), delivering viral supernatant, concentrated virus, purified virus, inactivated virus, split virus, and antigens.
  • Virology Services Comprehensive virology services performed in BSL-2 and BSL-3 facilities, including viral detection/quantification/characterization, vaccine response assays, infection and compound evaluation, quality control, epithelial fitness assessment, potency and antiviral testing, and drug combination studies, delivered to pharmaceutical and biotech clients.
  • Preclinical Models Integrated in vitro and in vivo preclinical models for evaluation of prophylactic and therapeutic candidates against respiratory viruses, combining cell line infection models, reconstituted human airway epithelium (HAE) models, and animal models (mouse, ferret, hamster, non-human primate) for translational research.

Quantifiable outcome

  • Supported HIPRA BIMERVAX vaccine approval by EMA (April 2023) through preclinical studies demonstrating efficacy against SARS-CoV-2 variants
  • +2 more outcomes

Companies that use virnext

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

virnext technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

virnext partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered flagship, core and minor.

  • RESPIVIR International Research Laboratory (France-Canada)flagshipStrategic or Co-development Partner · 11 October 2022International Associated Laboratory between Université Claude Bernard Lyon 1 (France) and Université Laval/CHU de Québec (Canada). Formalized in October 2022 with INSERM joint lab label in 2024. Focuses on origin, treatment, and prevention of respiratory viral infections. Led by Manuel Rosa-Calatrava and Guy Boivin with 15+ years of collaboration history.
  • ViroCrib ConsortiumflagshipStrategic or Co-development PartnerCNRS-initiated national screening infrastructure for antiviral molecules across complementary preclinical models. VirNext contributes viral library, combinatorial screening expertise, and continuum of predictive in vitro and in vivo infection models.
  • CynbiosecoreStrategic or Co-development PartnerPublic-private partnership since 2017 for evaluation of drugs, vaccines, and antibody candidates against respiratory viruses. Combines VirNext's in vitro/in vivo models with Cynbiose's NHP expertise for complete preclinical service packages.
  • EpithelixcoreTechnology or IntegrationPartnership for in vitro SARS-CoV-2 and respiratory virus infection models based on reconstituted human respiratory tissues at air-liquid interface (MucilAir, Smallair). Epithelix provides 3D reconstituted human lung tissue; VirNext performs infections in BSL-3/BSL-2 facilities.
  • Cynbiome AlliancecoreStrategic or Co-development PartnerExcellence preclinical research network dedicated to microbiome and infectious diseases. VirNext provides expertise in respiratory viruses and preclinical infection models. Led by Cynbiose with support from French government, BpiFrance, and Région Auvergne-Rhône-Alpes.
  • VaxxelcoreOEM/ Whitelabel/ Licensing PartnerSpin-off from RESPIVIR and VirNext developing METAVAC live-attenuated intranasal vaccines against RSV and HMPV. Exclusive worldwide license for METAVAC platform. Founded 2019 in Lyon.
  • Signia TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerSpin-off licensing diltiazem-based antiviral compositions for treatment of influenza and SARS-CoV-2. Uses VirNext's SIGNATURA platform for drug identification and repurposing as broad-spectrum host-directed inhibitors.
  • VirexpRcoreOEM/ Whitelabel/ Licensing PartnerSpin-off focused on indoor air quality and contamination management. Develops test benches for evaluating air treatment technologies against respiratory viruses. Founded from VirPath lab and VirNext platform expertise.
  • NexomisminorOEM/ Whitelabel/ Licensing PartnerSpin-off launched 2024 providing bioinformatics and NGS data exploitation services. Technological support platform based on AI, mathematics, and system administration expertise.
  • AIS BiotechminorOEM/ Whitelabel/ Licensing PartnerSpin-off founded 2023 developing anti-infective therapeutics based on sugar-derived biopolymers. Lead candidate GlycoFlu for influenza. Leverages VirNext's virology expertise and preclinical capabilities.
  • A*STAR Infectious Diseases LabscoreStrategic or Co-development PartnerInternational partnership through IMMUNOVIR program structured around immune response studies, diagnostic technology development, and anti-infective immunotherapy strategies. Supported by PHCMERLION program between UCBL1 and A*STAR.
  • HIPRAcoreStrategic or Co-development PartnerSpanish pharmaceutical company. VirNext performed preclinical evaluation of BIMERVAX COVID-19 vaccine candidate in NHP models, contributing to EMA approval in April 2023.
  • GIMAPminorStrategic or Co-development PartnerResearch unit at Jean Monnet University (Saint-Étienne) focused on mucosal immunology, inflammation, and infection. Collaboration through RESPIVIR for mucosal vaccine and immunotherapy strategies.
  • VirPath LaboratoryflagshipStrategic or Co-development PartnerAcademic laboratory at CIRI (INSERM U1111 - CNRS UMR 5308) specializing in virology and human respiratory pathologies. Hosts National Reference Center for Respiratory Viruses. VirNext is spin-off (EZUS Lyon) of VirPath.
  • ASPIDAminorStrategic or Co-development PartnerDeeptech company specialized in ultra-critical containment. Partner in SHIELD project for developing innovative controlled environment solutions for airborne infectious risk control in hospitals.
  • CONIDIAminorStrategic or Co-development PartnerStrategic and commercial partnership with VirexpR for assessing air treatment and respiratory protection technologies in atmospheres contaminated by infectious mixtures.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

virnext competitors and assessment

Company assessment

Direct peers

  • hVIVO: UK-based CRO running human respiratory virus challenge trials and preclinical virology services for pharma and biotech. Comparable to VirNext on respiratory-virus specialization, BSL capability, and customer base of pharma/biotech developing antivirals and vaccines.
  • Viroclinics Biosciences: Dutch CRO specializing in respiratory virus and influenza preclinical/clinical services including BSL-3 capabilities and antiviral/vaccine evaluation. Closest functional peer to VirNext in Europe given overlapping respiratory-virus focus and similar contract-research service model.
  • Cynbiose: French CRO specializing in non-human primate preclinical studies, VirNext's named NHP partner and member of the Cynbiome alliance. Directly comparable on BSL-3 in vivo respiratory virus evaluation and serves the same French/European biotech-pharma customer segment.
  • NeoVirTech: French preclinical CRO offering antiviral and virucidal testing services with BSL-2/BSL-3 capabilities, listed on VirNext's partner page. Directly comparable specialized respiratory/antiviral CRO competing for similar French and European biotech-pharma contracts.
  • Epithelix: Swiss provider of 3D reconstituted human airway epithelium models (MucilAir, Smallair) and respiratory toxicology/virology services. A named VirNext technology partner that competes and collaborates in HAE-based respiratory virus testing for pharma and cosmetics clients.

Broad incumbents

  • SGS: Global testing, inspection, and certification company with significant health and nutrition/pharmaceutical services including virology and BSL-2/BSL-3 testing. A broad incumbent whose scale and geographic reach compete with VirNext for outsourced virology services.
  • Charles River Laboratories: Global CRO offering end-to-end preclinical research including vaccine and antiviral safety/efficacy studies with BSL capabilities. A broad incumbent that competes with VirNext on bundled preclinical respiratory-virus programs from large pharma clients.

Emerging players

  • ImQuest BioSciences: US CRO focused on anti-infective and antiviral preclinical development, including respiratory virus evaluation and BSL-3 work. Comparable emerging specialized CRO with similar antiviral and vaccine candidate evaluation service lines.
  • Vaxxel: French biotech spin-off from RESPIVIR/VirNext developing METAVAC-based intranasal live-attenuated vaccines against RSV and HMPV. Comparable emerging vaccine developer leveraging VirNext's IP and platform; relevant peer as a downstream customer and proof point for VirNext's IP monetization model.
  • IBT Bioservices: US-based infectious disease CRO offering in vivo and in vitro virology, immunology, and BSL-2/BSL-3 services for vaccines and antivirals. Comparable emerging specialized CRO with overlapping respiratory-virus and infectious-disease preclinical focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

virnext social profiles

Digital presence

virnext financial estimates

Financial estimate

Revenue estimate

Valuation estimate

virnext leadership team

Management profile

Number of profiles

Profiles10 records

virnext funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

virnext M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about virnext

What does virnext do?

VirNext is a technology research platform and contract research organization specializing in respiratory viruses. It provides fee-for-service virus production, virology testing, and preclinical evaluation of vaccine and antiviral candidates through in vitro cell line models, 3D reconstituted human airway epithelium (HAE) models, and in vivo animal models (mouse, ferret, hamster, non-human primate), all operated from integrated BSL-2 and BSL-3 facilities in Lyon, France.

Is virnext a public or private company?

virnext is a private company. It is classified as corporate owned and is currently operating.

When was virnext founded?

virnext was founded in 2012. It employs 1 to 10 people.

Where is virnext based?

virnext is headquartered in Lyon, France, in the Europe region.

How does virnext make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are technology Licensing.

Who are virnext's main competitors?

Direct peers on record are hVIVO, Viroclinics Biosciences, Cynbiose, NeoVirTech and Epithelix. Broad incumbents are SGS and Charles River Laboratories. Emerging players are ImQuest BioSciences, Vaxxel and IBT Bioservices.

Does virnext have an API?

No public API is recorded for virnext.

What industry is virnext in?

virnext's product category is Preclinical Research Services. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAJAIAI, Zoonotic & One Health Public Health Laboratory Networks. Its NAICS code is 621511 and its SIC code is 8734.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales